Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)
Meropenem is one of the most widely used special-grade antimicrobial agents in the treatment of neonatal sepsis. However, its irrational use has led to an increasingly severe problem of bacterial multidrug resistance. The guideline was developed following standardized methods and procedures, and provides 12 recommendations specifically addressing 9 clinical issues. The recommendations cover various aspects of meropenem use in neonates, including timing of administration, recommended dosage, extended infusion, monitoring and assessment, antimicrobial adjustment strategies, treatment duration, and treatment strategies for carbapenem-resistant Enterobacteriaceae infections. The aim of the guideline is to provide evidence-based recommendations and guidance for the rational use of meropenem in neonates with sepsis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics - 26(2024), 2 vom: 15. Feb., Seite 107-117 |
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
美罗培南治疗新生儿脓毒症的临床实践指南（2024年版） |
|---|
| Beteiligte Personen: |
|---|
| Links: |
|---|
| Themen: |
Clinical practice guideline |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 10.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.7499/j.issn.1008-8830.2309059 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369261763 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369261763 | ||
| 003 | DE-627 | ||
| 005 | 20240310232019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.7499/j.issn.1008-8830.2309059 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1322.xml |
| 035 | |a (DE-627)NLM369261763 | ||
| 035 | |a (NLM)38436306 | ||
| 035 | |a (PII)1008-8830(2024)02-0107-11 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 0 | |a Guideline Development Group of Clinical Practice Guidelines for Meropenem Therapy in Neonatal Sepsis; PekingUniversity Third Hospital; Editorial Department of Chinese Journal of Contemporary Pediatrics |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024) |
| 246 | 3 | 3 | |a 美罗培南治疗新生儿脓毒症的临床实践指南（2024年版） |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 10.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Meropenem is one of the most widely used special-grade antimicrobial agents in the treatment of neonatal sepsis. However, its irrational use has led to an increasingly severe problem of bacterial multidrug resistance. The guideline was developed following standardized methods and procedures, and provides 12 recommendations specifically addressing 9 clinical issues. The recommendations cover various aspects of meropenem use in neonates, including timing of administration, recommended dosage, extended infusion, monitoring and assessment, antimicrobial adjustment strategies, treatment duration, and treatment strategies for carbapenem-resistant Enterobacteriaceae infections. The aim of the guideline is to provide evidence-based recommendations and guidance for the rational use of meropenem in neonates with sepsis | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical practice guideline | |
| 650 | 4 | |a Meropenem | |
| 650 | 4 | |a Neonate | |
| 650 | 4 | |a Sepsis | |
| 650 | 7 | |a Meropenem |2 NLM | |
| 650 | 7 | |a FV9J3JU8B1 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics |d 2006 |g 26(2024), 2 vom: 15. Feb., Seite 107-117 |w (DE-627)NLM161132898 |x 1008-8830 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:2 |g day:15 |g month:02 |g pages:107-117 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7499/j.issn.1008-8830.2309059 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 2 |b 15 |c 02 |h 107-117 | ||